Conference Coverage > AASLD 2015
With an aging veteran population there are a number of conditions that need to be treated in these patients as well as others of their generation, particularly in when it comes to liver disease. Lauren Beste, MD, MSc, from the VA Puget Sound Health Care System in Seattle discussed a recent study looking at how conditions like cirrhosis and hepatocellular carcinoma are treated and the prevalence of these conditions in the veteran population during the recent Liver Meeting in San Francisco.
Source
AASLD Coverage
Q&A With Melissa Harris From Bristol-Myers Squibb: Expanding Hepatitis C Treatment To New Genotypes And Populations VIDEO
Nov 16, 2015 | AASLD 2015 | Adam Hochron
Hepatitis C is becoming a more commonly treated condition in many of its genotypes while others continue to present problems for the pharmaceutical and medical communities. Work is being done to overcome those challenges around the world.
Alcoholic Hepatitis: Filtering Device Helped Younger, Less Ill Patients
Nov 14, 2015 | AASLD 2015 | Gale Scott
A human-cell-based liver support system meant to keep patients alive despite acute liver failure did not help overall survival in a trial, but showed promise for a subset of patients. Those patients were younger and not as sick—though all subjects enrolled had alcoholic hepatitis.
Hepatitis C: Looking for an Effective Regimen for Genotype 3
Nov 14, 2015 | AASLD 2015 | Gale Scott
Hepatitis C genotype 3 can be hard to cure, but researchers presenting a study at the Liver Meeting (AASLD) in San Francisco, CA, said they have found a regimen that works.
HCV in Egypt: Success in Treating Genotype 4
Nov 14, 2015 | AASLD 2015 | Gale Scott
Egypt has the highest prevalence of hepatitis C in the word and most of it (90%) is genotype 4. Researchers presenting a study at the Liver Meeting (AASLD) in San Francisco, CA, reported success in a trial of ravidasvir
Insurance Lagging on Paying for HCV Antivirals
Nov 14, 2015 | AASLD 2015 | Gale Scott
The high costs of direct-acting antivirals to treat hepatitis C infection is no secret, but neither is the fact that the drugs are cost-effective. Pennsylvania researchers found insurers were lagging in approving payment for the drugs in their four-state region, with Medicaid programs the worst offenders.
HCV Antiviral Resistance a Challenge
Nov 14, 2015 | AASLD 2015 | Gale Scott
Despite the success of direct antivirals in curing hepatitis C, there are concerns about resistance to the drugs.
No comments:
Post a Comment